Fatty Liver Disease (MASLD)
Fat accumulation in the liver — newly renamed MASLD, extremely common, and responsive to weight loss.
Metabolic dysfunction-associated steatotic liver disease — the condition long called non-alcoholic fatty liver — is fat quietly accumulating in liver cells, present in a third or more of adults and usually discovered via mildly elevated liver enzymes or an incidental scan. A subset progresses to inflammation (MASH), scarring, and cirrhosis.
It is among the most weight-responsive conditions in medicine: losing roughly 7–10% of body weight measurably reduces liver fat and inflammation, squarely within GLP-1-era reach, and semaglutide has shown direct benefit in MASH trials. For patients, a fatty-liver note in old records is both a motivation and a disclosure item for the consultation — it shapes monitoring, not eligibility, in most cases.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Fatty Liver Disease? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment